Study findings indicated a transition from IV to enteral triazole therapy as a feasible option for pediatric patients with invasive candidiasis.

Pediatr Crit Care Med. 2013;14(6):e268-72. IV colistin was well tolerated in most of our critically ill children, and only five children had development of renal impairment after starting colistin ...

Background and aims: The aim is to evaluate and compare the efficacy and side effects of oral and intravenous(IV) ibuprofen for treatment of PDA in preterm infants. Methods: A prospective ...

According to Celltrion, STEQEYMA is expected to be marketed in the United States beginning in February 2025. DISCLAIMER: Because of the generality of this update, the information provided herein may ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo ...